Holy Basil in The Treatment of Dyspepsia (NCT07175272) | Clinical Trial Compass
RecruitingPhase 2/3
Holy Basil in The Treatment of Dyspepsia
Thailand27 participantsStarted 2026-02-13
Plain-language summary
The goal of this clinical trial is to evaluate whether holy basil extract can reduce gastric inflammation and improve symptoms in adult patients with dyspepsia.
The main questions it aims to answer are:
* Does holy basil extract reduce gastric mucosal inflammation as measured by histopathology?
* Does holy basil extract improve dyspeptic symptoms, endoscopic findings, gastric pH, duodenal eosinophil counts, and systemic inflammation (serum IL-6)?
Participants will:
* Take 300 mg of holy basil extract orally once daily for 28 days
* Complete symptom questionnaires and diaries during treatment
* Undergo upper endoscopy with biopsy and intragastric pH monitoring before and after treatment
* Provide blood samples for inflammatory marker measurement
* Be monitored for safety and adverse events
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participants aged 18 years and older.
* Presence of dyspeptic symptoms, assessed by the Leeds Dyspepsia Questionnaire with a score of at least 5 or higher.
Exclusion Criteria:
* Presence of Helicobacter pylori infection.
* Diagnosis of peptic ulcer or erosive esophagitis Los Angeles Classification grade B or greater.
* Use of acid-suppressant therapy including proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) that cannot be discontinued at least 2 weeks prior enrolment and during the study period.
* Use of mucosal protective agents, such as rebamipide, sucralfate, or irsogladine that cannot be discontinued at least 4 weeks prior enrolment and during the study period.
* History of gastric cancer or duodenal cancer.
* Previous upper gastrointestinal surgery.
* Current pregnancy or lactation.
* Known allergic to the medicine.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in gastric mucosal inflammation score by histopathology
Timeframe: From baseline to the end of treatment at 28 days